Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Infographic

China flag thumb

China’s bribery probe goes national

Expands investigation that already affects GSK, Sanofi, Lilly, AZ, Lundbeck, Novo and UCB

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

EU flag

EC sets up expert group on rare diseases

Will revamp EUCERD to better handle development of orphan medicines

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

Actelion HQ Switzerland

Actelion to buy Ceptaris – if FDA backs its cancer treatment

Acquisition contingent on Valchlor approval in rare lymphoma

BTG extends orphan drug distribution partnership with Clinigen

Deal covers treatment for overexposure to chemotherapy

- PMLiVE

GSK replaces China head as bribery probe rolls on

Herve Gisserot takes over from Mark Reilly

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

Infographic: Pharma investment in Indonesia

Pharma deals in the region since the introduction of Decree 1010 to force companies to manufacture products locally

Enabling access for patients with rare diseases

When it comes to meeting patient needs, the well-known counsel to ‘think globally, act locally’ rings true

- PMLiVE

GSK concedes execs may have broken Chinese law

President of international operations suggests senior execs were involved in bribery scandal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links